Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.